Spruce Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SPRB Nasdaq 2836 sprucebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Spruce Biosciences, Inc.

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital - Jan 8th, 2026 6:00 am
Spruce Biosciences initiated with an Outperform at Oppenheimer - Dec 24th, 2025 4:30 am
Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls - Dec 23rd, 2025 7:33 am
Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More - Dec 23rd, 2025 6:13 am
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors - Dec 15th, 2025 6:00 am
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - Nov 10th, 2025 2:05 pm
What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now? - Oct 15th, 2025 10:00 am
Spruce Biosciences Announces $50.0 Million Private Placement Financing - Oct 8th, 2025 6:00 am
Why Spruce Biosciences Just Skyrocketed Almost 1,400% - Oct 6th, 2025 2:59 pm
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) - Oct 6th, 2025 6:00 am
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market - Sep 15th, 2025 5:00 am
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - Aug 14th, 2025 2:05 pm
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB) - Aug 14th, 2025 2:00 pm
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates - Aug 7th, 2025 3:55 pm
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates - Aug 5th, 2025 7:10 am
Illumina (ILMN) Q2 Earnings and Revenues Surpass Estimates - Jul 31st, 2025 3:35 pm
Spruce Biosciences Announces Reverse Stock Split - Jul 24th, 2025 2:01 pm
HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder - Jul 22nd, 2025 8:31 am
Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market - Jun 12th, 2025 6:00 am
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - May 6th, 2025 2:01 pm